Nexstim

Nexstim is a Finnish medical technology company headquartered in Helsinki, specializing in navigated brain stimulation for both clinical and therapeutic applications. The company develops and markets two flagship systems: the NBS System, used for presurgical mapping of eloquent brain areas, and the NBT System, designed to deliver transcranial magnetic stimulation for the treatment of major depressive disorder. Both platforms are built on Nexstim's proprietary eXimia technology, which integrates individual patient MRI data with real-time neuronavigation to deliver precisely targeted magnetic pulses to defined cortical regions. This image-guided approach distinguishes Nexstim's technology from conventional TMS systems by enabling a level of anatomical precision that is largely unmatched in the field.

Nexstim is publicly traded on the Helsinki Stock Exchange, reflecting its established presence in the European medtech landscape and its ongoing commitment to transparency and growth. The NBS System has received regulatory clearance in major markets including the United States and Europe, and has been adopted by leading neurosurgical centers globally for preoperative cortical mapping. The NBT System has advanced through clinical development for major depressive disorder, positioning the company within the rapidly expanding market for non-invasive neuromodulation therapies. These milestones underscore Nexstim's progress in translating sophisticated neuroscience into commercially viable and clinically validated tools.

Nexstim represents a meaningful contributor to the broader neurotech industry by demonstrating how navigated, patient-specific approaches can elevate the standard of care in both neurosurgery and psychiatric treatment. As the neuromodulation space grows increasingly competitive, Nexstim's emphasis on precision and evidence-based application offers a differentiated value proposition that bridges diagnostics and therapy. The company's dual-market strategy, spanning neurosurgical planning and mental health treatment, positions it at the intersection of two high-growth segments within neurotechnology. For an industry still working to establish reproducibility and targeting accuracy as core standards, Nexstim's technology serves as an important proof point for what image-guided neuromodulation can achieve.